Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
Lindsey Draper, MD serves as an Adjunct Instructor in the Roybal Laboratory within the Department of Medicine, Division of Hematology and Oncology at the University of California San Francisco School of Medicine. Her clinical practice focuses on the treatment of patients with recurrent ovarian cancer using systemic therapies including chemotherapy and immunotherapy, with a commitment to evaluating and offering clinical trial opportunities as part of individualized patient care. Dr. Draper completed her educational training with a B.S. in Biology from Juniata College (2010), an M.D. from the University of Maryland School of Medicine (2017), an Internal Medicine Residency at The Mount Sinai Hospital (2022), and is currently completing a Medical Oncology Fellowship at UCSF (2025-2027). Her research interests center on cancer immunotherapy, particularly T cell-based approaches for HPV-associated cancers and ovarian cancer. She investigates engineered T cell therapies targeting viral antigens in cervical and other HPV-related cancers, with a focus on overcoming treatment resistance and improving clinical outcomes through novel immunotherapeutic strategies. Her work bridges fundamental immunological mechanisms with clinical applications, emphasizing the translation of laboratory discoveries into patient treatments. Dr. Draper's publication record demonstrates consistent contributions to the field of cancer immunotherapy, with recent work focusing on TCR-engineered T cells for leukemia and HPV-associated malignancies. Her research trajectory shows increasing sophistication in T cell engineering approaches and a growing emphasis on addressing inflammatory responses and treatment resistance mechanisms. Parker Institute for Cancer Immunotherapy Early Career Research Award: Parker Scholar (2024) Gladstone-UCSF Institute of Genomic Immunology Symbiont Seed Grant for 'Antigen Discovery for Ovarian Cancer' (2024) Conquer Cancer Young Investigator Award, American Society of Clinical Oncology (2024) Women in Cancer Immunotherapy Network Leadership Institute Selected Participant, Society for Immunotherapy of Cancer (2024) Physician-Scientist Fellow, Chan Zuckerberg Biohub - San Francisco (2023-2025) As a physician-scientist, Dr. Draper maintains an active research program while providing clinical care, with particular emphasis on developing novel immunotherapies for gynecologic cancers. Her current fellowship at UCSF and multiple early-career awards indicate strong potential for continued contributions to the field of cancer immunotherapy. Dr. Draper works within the Roybal Laboratory at UCSF, which focuses on innovative approaches to cancer immunotherapy and T cell engineering. Her research intersects with multiple collaborative initiatives at UCSF, including the Parker Institute for Cancer Immunotherapy and the Gladstone-UCSF Institute of Genomic Immunology.
Prof. Dr. Helmuth Gehart is a faculty member at the Institute of Molecular Health Sciences , ETH Zurich . He leads the Tumor and Stem Cell Dynamics research group, focusing on dynamic cell identity in regeneration and cancer. Research Interests : Stem cell-environment interactions, organoid technology, single-cell sequencing, and mechanisms of tissue repair/tumorigenesis. Publications : 10+ articles (2015-2024) on organoid models, stem cell dynamics, and cancer biology.
Daiwei (David) Zhang, PhD, is an Assistant Professor (tenure-track) in the Department of Biostatistics at the University of North Carolina at Chapel Hill School of Medicine, with a joint appointment in the Department of Genetics. His research focuses on developing AI frameworks for analyzing high-dimensional biomedical data, particularly in spatial omics, computational pathology, and medical imaging. Education: MS (Biostatistics) and PhD (Biostatistics and Scientific Computing) from the University of Michigan. Postdoctoral Training: University of Pennsylvania. Research interests include applying machine learning to address biomedical challenges such as tumor heterogeneity, immune interactions, and tissue architecture. His work spans computational methods for spatial transcriptomics, proteomics, and histology integration. Recent publications emphasize spatial multi-omics analysis of cancer ecosystems, tertiary lymphoid structures, and metabolic coordination. These studies leverage advanced machine learning algorithms and interdisciplinary approaches to advance precision medicine. No scientific awards are explicitly mentioned, but his work reflects significant contributions to biomedical AI research. Grants and advising details are not provided in the text.
Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program. B.S. in Physics (Nanjing University, 2005) M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008) M.S. in Electrical and Computer Engineering (Purdue University, 2009) Ph.D. in Mechanical Engineering (University of Michigan, 2014) His research focuses on Lab-on-a-Chip , Organ-on-Chip systems, Biomaterials , and Mechanobiology , with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics. Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding. National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling National Institutes of Health (NIH) awards for immunotherapy research American Heart Association fellowships and institutional training programs Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation. He leads the Applied Micro-Bioengineering Laboratory (AMBL) , which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.
Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu
About Dr. Pegah Varamini Dr. Pegah Varamini is a Senior Lecturer in Pharmacy and Pharmacology at the Sydney Pharmacy School, University of Sydney, and a Casual Lecturer in Music Education at the Sydney Conservatorium of Music. She leads the Breast Cancer Targeting & Drug Delivery (BCTDD) Group, focusing on innovative drug delivery systems for Triple Negative Breast Cancer (TNBC). Her research integrates nanotechnology, targeted therapy, and translational medicine, supported by prestigious grants including the NBCF Fellowship (2016). Research & Education PharmD (Shiraz University of Medical Sciences) PhD in Pharmaceutical Sciences (University of Queensland) Second PhD in Music Education (University of Sydney Conservatorium of Music) Key Research Interests Her work centers on: Peptide-based targeting strategies using 'Trojan Horse' approaches for TNBC Development of nanomedicine for bone metastasis prevention Clinically relevant preclinical models for personalized breast cancer treatment Collaborations with international institutions (e.g., Harvard Medical School, University of Nantes) Teaching & Supervision Dr. Varamini coordinates Drug Design and Development (PCOL3012/3912) and supervises a multidisciplinary team of HDR students and postdoctoral researchers. Notable current students include PhD candidate Hany Ghaly and MPhil candidates Huimin Shao and Farhana Mollah. Awards & Recognition 2021 Equity Prize 2016 Top 25 Young Researchers of Australia and New Zealand 2018 Fresh Scientist of the Year Recipient of multiple grants totaling over AUD 2M Leadership & Outreach She co-chairs the Nanopharma cluster at Sydney Nano Institute and advises the WHO Global Breast Cancer Initiative. Her work has been featured in media outlets such as SBS Farsi News and NBCF publications.
Dr. Susan Hua is an Associate Professor at the University of Newcastle's School of Biomedical Sciences and Pharmacy, specializing in translational nanopharmaceutics and therapeutic targeting. She established the first translational nanopharmaceutics laboratory in the Hunter region, focusing on drug delivery systems for gastrointestinal, musculoskeletal, and reproductive pathologies. Education: Bachelor of Pharmacy with Honours, University of Queensland (UQ) PhD in Neuroscience and Nanotechnology, UQ Research Interests: Her work centers on using nanotechnology to create targeted drug delivery systems for diseases such as chronic pain, inflammatory conditions, and obstetric complications. Key focuses include oxytocin receptor-targeted liposomes for uterine therapies and localized drug delivery to bypass biological barriers. Awards & Recognition: 2020 DVC(A) Educator Innovation Award 2017 NSW Premier's Early Career Researcher of the Year 2015 HMRI Early Career Researcher of the Year Grants & Collaborations: A/Prof Hua has secured over $5.5M in grants, including NHMRC and ARC funding. She collaborates with institutions like HMRI, John Hunter Hospital, and global teams on projects like nanoparticle-based treatments for preterm labor and uterine hemorrhage. Teaching & Leadership: She coordinates pharmacy programs, emphasizing clinical application and innovation. Her courses include Pharmacotherapeutics and Pharmacy Practice, with awards for teaching excellence (2020, 2011). Labs & Programs: Head of Therapeutic Targeting Program, University of Newcastle Director, Translational Pharmaceutics & Medical Technologies Theme (HMRI)
Sara Gallini is an Assistant Professor at EPFL, leading the Gallini Lab within the ISREC Department of the School of Engineering (SV). Her research focuses on understanding how healthy and oncogenic cells compete in skin epithelium, aiming to identify therapeutic targets for skin cancer prevention. She holds a Tenure Track position and teaches in the Life Sciences Engineering program. Her lab employs advanced in vivo imaging and single-cell analysis techniques. Education details are not explicitly provided, but her career includes a postdoctoral fellowship with the HFSP. Her research integrates molecular, cellular, and systems-level approaches to study cancer initiation and tissue homeostasis, particularly in injury-driven dynamics. Lab Members: Includes PhD student Mustafa Öztürk and technical staff Mélanie Sipion. Key Research Themes: Oncogenic cell competition, epidermal regeneration, EGFR/ERK signaling, and therapeutic target discovery. Her lab collaborates with clinical teams and uses models like mouse skin to study tumor suppression mechanisms. Future work aims to leverage healthy cell dynamics for cancer treatment strategies. Contact: SV 2527 office, +41216936764, sara.gallini@epfl.ch .
Guoyao Wu is a Distinguished Professor of Animal Nutrition at Texas A&M University's College of Agriculture & Life Sciences, holding dual appointments in the Department of Animal Science and the Graduate Faculty of Nutrition. His expertise spans nutritional biochemistry, protein metabolism, and reproductive physiology. Dr. Wu earned his B.Sc. from South China Agricultural University, M.Sc. degrees from Beijing Agricultural University and the University of Alberta, and a Ph.D. from the University of Alberta, followed by postdoctoral training at McGill University and Memorial University of Newfoundland. His research focuses on amino acid and protein metabolism across molecular, cellular, and whole-animal levels, using models like cattle, pigs, and aquatic species. Key areas include placental nutrient transport, fetal programming, and the role of amino acids in mitigating conditions like sarcopenia and intrauterine growth restriction. He has pioneered studies on glycine, creatine, and citrulline supplementation in livestock and aquaculture. Dr. Wu has received over 15 prestigious awards from China, Canada, and the U.S., including the Thousand-People-Talent Award and Changjiang Scholar Award. He serves on editorial boards of journals like Amino Acids and Frontiers in Bioscience , and teaches graduate courses in protein metabolism. His work bridges basic science and applied nutrition, with implications for improving livestock productivity, human health, and aquaculture sustainability. Current projects address amino acid requirements of companion animals, microgravity effects on metabolism, and placental biology in ruminants.
Harri Lähdesmäki is an Associate Professor (tenured) at the Department of Computer Science, Aalto University, where he leads the Computational Systems Biology research group. His work focuses on probabilistic machine learning and deep generative models with applications in biomedicine and molecular biology. Key Research Interests: Probabilistic machine learning, deep generative models, computational biology, bioinformatics, longitudinal data modeling Contact: harri.lahdesmaki@aalto.fi | Konemiehentie 2, 02150 Espoo, Finland His recent publications highlight advancements in: Gaussian process priors for scalable deep generative models Single-cell analysis of immune repertoires in leukemia and diabetes Probabilistic deconvolution methods for RNA-seq data Epigenetic analysis using hidden Markov and mixed models Transformer-based survival prediction and missing data handling Harri’s work integrates mechanistic modeling with Bayesian inference, particularly applied to immunology, cancer biology, and early disease prediction.
Carmen Bergom, MD, PhD, is an Associate Professor of Radiation Oncology at Washington University School of Medicine (WashU Medicine), where she joined the faculty in 2020. She holds secondary appointments in the Division of Cancer Biology and the Siteman Cancer Center. Her research focuses on leveraging genetic models to improve radiation therapy efficacy while mitigating radiation-induced cardiotoxicity , particularly in breast cancer patients. Key areas include radiation biology , tumor microenvironment , and cardio-oncology . Recent publications highlight her work in genetic mapping of radiation sensitivity (e.g., rat chromosome 3 variants), innovative imaging techniques (e.g., integrin-targeted PET), and clinical trial design for cardiovascular risk stratification. Her laboratory has pioneered the first genetic studies of radiation-induced cardiac dysfunction. Scientific awards include the Michael Fry Research Award (2021) and recognition as a Top Doctor in America (2018, 2019). She serves as Chair of the ASTRO Science Council Scientific Review Panel and co-chair of the Clinical and Experimental Research in Radiation Oncology meeting at ESTRO. Dr. Bergom treats breast cancer patients clinically and mentors students across all levels (undergraduate to postdoctoral). Her work bridges basic research with clinical applications , aiming to develop biomarkers and therapeutic targets for radiation oncology.
Dan A. Dixon is a Professor and Associate Director of Community Outreach and Engagement at the Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences (UAMS), where his research focuses on post-transcriptional gene regulation mechanisms in cancer pathogenesis. His academic credentials include: Ph.D. from Northwestern University B.A. from Augustana University Dr. Dixon's research centers on RNA-binding proteins (notably HuR and tristetraprolin) and their role in destabilizing oncogenic mRNA networks. His laboratory investigates how dysregulation of these post-transcriptional controllers permits overexpression of tumor-promoting genes involved in proliferation, angiogenesis, and metastasis. Key focus areas include colorectal cancer mechanisms, autophagy regulation via Rab27B, stress granule dynamics in mutant p53 contexts, and extracellular vesicle-mediated tumor microenvironment activation. Analysis of his 2022-2025 publications reveals intensifying work on XPO1 inhibition for colorectal cancer chemoprevention, Rab27B-autophagy axis characterization, and mutant p53 vulnerabilities. His studies consistently employ molecular techniques, mouse models (APC Min/+ ), and translational approaches to identify biomarkers and therapeutic targets. Dr. Dixon maintains active laboratory facilities at WPRCI 947 and 951, directing research that bridges fundamental RNA biology with clinical oncology applications. His leadership in community outreach complements his bench-to-bedside research philosophy.
